Reply to Kobayashi et al.: Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis

Affiliations

Comment

Yasuhiro Kondoh et al. Am J Respir Crit Care Med. 2020.

. 2020 Jun 1;201(11):1450-1451.

doi: 10.1164/rccm.202002-0398LE.

No abstract available

Comment on

Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial.
Kondoh Y, Azuma A, Inoue Y, Ogura T, Sakamoto S, Tsushima K, Johkoh T, Fujimoto K, Ichikado K, Matsuzawa Y, Saito T, Kishi K, Tomii K, Sakamoto N, Aoshima M, Araya J, Izumi S, Arita M, Abe M, Yamauchi H, Shindoh J, Suda T, Okamoto M, Ebina M, Yamada Y, Tohda Y, Kawamura T, Taguchi Y, Ishii H, Hashimoto N, Abe S, Taniguchi H, Tagawa J, Bessho K, Yamamori N, Homma S. Kondoh Y, et al. Am J Respir Crit Care Med. 2020 May 1;201(9):1110-1119. doi: 10.1164/rccm.201909-1818OC. Am J Respir Crit Care Med. 2020. PMID: 31917621 Clinical Trial.
Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis.
Kobayashi T, Hataji O, Fujimoto H, D'Alessandro-Gabazza C, Yasuma T, Gabazza EC. Kobayashi T, et al. Am J Respir Crit Care Med. 2020 Jun 1;201(11):1449-1450. doi: 10.1164/rccm.202002-0271LE. Am J Respir Crit Care Med. 2020. PMID: 32150439 Free PMC article. No abstract available.

1. Kondoh Y, Azuma A, Inoue Y, Ogura T, Sakamoto S, Tsushima K, et al. Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis: a randomized, double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2020;201:1110–1119. - PubMed
1. European Medicines Agency / Committee for Medicinal Products for Human Use (CHMP) Guideline on the investigation of subgroups in confirmatory clinical trials; 2019 [updated 2019 Jan 31; accessed 2020 Feb 21]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-in....
1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. - PMC - PubMed
1. Kataoka K, Taniguchi H, Kondoh Y, Nishiyama O, Kimura T, Matsuda T, et al. Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2015;148:436–443. - PubMed
1. Isshiki T, Sakamoto S, Kinoshita A, Sugino K, Kurosaki A, Homma S. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respiration. 2015;89:201–207. - PubMed